Cagrilintide, single vial

Long-acting amylin receptor agonist

Cagrilintide

Long-acting amylin receptor agonist. Supplied for laboratory research use only.

  • Amylin receptor agonist; also one half of the combination drug CagriSema
  • Monotherapy Phase 2 published in The Lancet, 2021: 706 adults, 26 weeks
  • Not approved anywhere, alone or in combination
  • Supplied for laboratory research use only. Not for human or veterinary use.
$239.99$359.97 Save 33%
Every vial 10 mg
Choose your supply
Most Popular
Best Value
In stock, ready to ship

90-Day Money-Back Guarantee

Every order is covered for ninety days from delivery. If you decide against it inside that window, contact us and we will refund the purchase price.

Research use only. Not for human or veterinary use or consumption. This product is not approved by the FDA and is not intended to diagnose, treat, cure or prevent any disease.

What it is
CompoundCagrilintide
ClassLong-acting amylin receptor agonist
FormLyophilised powder, supplied in a vial
OriginatorNovo Nordisk
Development status

Cagrilintide is an investigational compound and is not approved by the FDA for any indication. It is in Phase 3 clinical trials under the REDEFINE programme.

Not approved as a standalone compound anywhere. Developed primarily as a component of the fixed-dose combination CagriSema (cagrilintide + semaglutide). A New Drug Application for CagriSema was submitted to the FDA in 2025 and is not approved as of this writing.

Shipping & returns
ReturnsNinety days from delivery. Contact us and we will refund the purchase price.
Cagrilintide $239.99

The specifics

The details, if you want them.

DeveloperNovo Nordisk
ClassLong-acting amylin receptor agonist
Amino acids37
Half-lifeapproximately 7–8 days
FormLyophilised powder
Receptor target(s)amylin receptor
Binding mechanismC20 eicosanedioic fatty diacid N-terminal acylation via a gamma-glutamic acid linker, enabling albumin binding

Development

Where it is up to.

Studied mainly as a component of the investigational combination CagriSema, which has an FDA application under review; not yet approved as of this writing.

Questions

The questions people actually ask.

What is cagrilintide?
A synthetic peptide developed by Novo Nordisk that acts on the amylin receptor. It's studied mainly as a component of the combination CagriSema.
Is cagrilintide approved by the FDA?
No, not as a standalone compound. Novo Nordisk filed an FDA application for the combination product CagriSema (with semaglutide) in 2025; it has not been approved.
What does "Research Use Only" mean?
Research Use Only means exactly that: intended for laboratory and research settings only, not for human or animal use, consumption, diagnosis, treatment, cure, or prevention of any disease.
How is cagrilintide supplied?
As a vial of lyophilised (freeze-dried) powder, sold for laboratory and research use only.
What is your refund policy?
Ninety days from delivery. If you decide against it inside that window, contact hello@getmrpeps.com and we will refund the purchase price. Damaged or incorrect orders are replaced or refunded regardless.